Skip to main content
SpringerLink
Log in

Pharmacoeconomics of Hypertension Management

The Place of Combination Therapy

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Pharmacological treatment of hypertension has been shown to reduce the risk of stroke, coronary events, heart failure and progression of renal disease. However, rates of successful blood pressure control remain low among treated patients while antihypertensive medication represents a large and increasing proportion of healthcare expenditure in many countries. Several influential pharmacoeconomic analyses have confirmed the cost effectiveness of conventional antihypertensive treatments, usually involving monotherapy with diuretics or β-blockers, compared with alternative strategies. Recent research has shown that a considerable proportion of the total cost of antihypertensive treatment in general practice is due to factors such as inadequate blood pressure control, poor compliance with therapy, discontinuation and switching between therapies. These factors operate to a much lesser extent in well-conducted clinical trials, and have not been fully incorporated into most economic studies. Some novel strategies, particularly low dose combinations of antihypertensive agents, may offer advantages in terms of efficacy, reduced adverse effects and improved compliance with treatment.

There is therefore a need for comprehensive pharmacoeconomic analyses of novel strategies, taking these additional factors into account. Until such studies are available, the wider use of low dose combination therapy and other novel strategies should not be held back on the basis of earlier economic studies that have not included all relevant considerations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Hilleman DE, Mohiuddin SM, Lucas BD, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994; 16: 88–102

    PubMed  CAS  Google Scholar 

  2. Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47-S54

  3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–6

    Article  PubMed  CAS  Google Scholar 

  4. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157 (21): 2413–46

    Article  Google Scholar 

  5. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305–13

    Google Scholar 

  6. Mancia G, Grassi G. Rationale for the use of a fixed combination in the treatment of hypertension. Eur Heart J 1999; 1 Suppl. L: L14-L19

    Google Scholar 

  7. Colhoun HM, Dong W, Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens 1998; 16: 747–52

    Article  PubMed  CAS  Google Scholar 

  8. Menard J, Cornu P, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992; 6: 447–58

    PubMed  CAS  Google Scholar 

  9. Elliott WJ. The costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics? Postgrad Med 1996; 99: 241–52

    PubMed  CAS  Google Scholar 

  10. Pardell H, Tressarras R, Armario P, et al. Pharmacoeconomic considerations in the management of hypertension. Drugs 2000; 59 Suppl. 2: 13–20

    Article  PubMed  Google Scholar 

  11. Bernard DB, Townsend RR, Sylvestri MF. Health and disease management: what is it and where is it going? What is the role of health and disease management in hypertension? Am J Hypertens 1998; 11: 103S-108S

    Article  Google Scholar 

  12. Prieto M, de Abajo FJ, Montero D, et al. Use of antihypertensive drugs in Spain, 1985–1995 [in Spanish]. Med Clin (Barc) 1998; 110: 247–53

    CAS  Google Scholar 

  13. Maynard A. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6: 417–20

    PubMed  CAS  Google Scholar 

  14. Heidenreich PA, Lee TT. What a physician needs to know about cost-effectiveness. Cardiol Rev 2000; 8: 96–102

    Article  PubMed  CAS  Google Scholar 

  15. Drummond M, Coyle D. Assessing the economic value of antihypertensive medicines. J Hum Hypertens 1992; 6: 495–501

    PubMed  CAS  Google Scholar 

  16. Wilson TW, Chockalingham A, Quest DW. Pharmacoeconomics of hypertension control: basic principles of economic evaluation. J Hum Hypertens 1996; 10 Suppl. 2: S19-S22

    Google Scholar 

  17. Jönsson BG. Cost-benefit of treating hypertension. J Hypertens 1994; 12 Suppl. 10: S65-S70

    Google Scholar 

  18. Fletcher A. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. J Hypertens 1991; 9: 193–8

    Article  PubMed  CAS  Google Scholar 

  19. Weinstein MC, Stason WB. Hypertension: a policy perspective. Cambridge (MA): Harvard University Press, 1976

    Google Scholar 

  20. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–9

    Article  PubMed  CAS  Google Scholar 

  21. Kannel WB, Gordon T, editors. The Framingham Study: an epidemiological investigation of cardiovascular disease. Sect. 30. Washington (DC): Government Printing Office, 1974

  22. Johannesson M, Hedbrant J, Jönsson B. A computer model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform (Lond) 1991; 16 (4): 355–62

    Article  CAS  Google Scholar 

  23. Johannesson M. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials. Med Decis Making 1994; 14: 236–44

    Article  PubMed  CAS  Google Scholar 

  24. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995; 7 (3): 242–50

    Article  PubMed  CAS  Google Scholar 

  25. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment. J Hum Hypertens 1996; 10 Suppl. 2; S23-S26

    Google Scholar 

  26. Kawachi I, Malcolm LA. The benefits of treating mild to moderate hypertension: a quantitative estimation of the life expectancy gains from pharmacological reduction of blood pressure. J Clin Epidemiol 1989; 42: 905–12

    Article  PubMed  CAS  Google Scholar 

  27. Kawachi I, Malcolm LA. Treating mild to moderate hypertension: cost-effectiveness and policy implications. J Cardiovasc Pharmacol 1990; 16 Suppl. 7: S126-S128

    Google Scholar 

  28. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199–208

    Article  PubMed  CAS  Google Scholar 

  29. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–38

    Article  PubMed  CAS  Google Scholar 

  30. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578–81

    Article  PubMed  CAS  Google Scholar 

  31. Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14: 683–9

    Article  PubMed  CAS  Google Scholar 

  32. MacMahon S. Guidelines for antihypertensive therapy. J Hypertens 1996; 14: 691–3

    Article  PubMed  CAS  Google Scholar 

  33. Swales JD. Treating hypertension. J Hypertens 1996; 14: 813–4

    Article  PubMed  CAS  Google Scholar 

  34. Zanchetti A, Mancia G. Editors’ corner: benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14: 809–11

    Article  PubMed  CAS  Google Scholar 

  35. Nissinen A, Tuomilehto J, Kottke TE, et al. Cost-effectiveness of the North Karelia Hypertension Program. Med Care 1986; 24: 767–80

    Article  PubMed  CAS  Google Scholar 

  36. Psaty BM, Smith NL, Sicovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997; 277: 739–45

    Article  PubMed  CAS  Google Scholar 

  37. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–64

    Article  PubMed  CAS  Google Scholar 

  38. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo on older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative group. J Hypertens 1998; 16: 1823–9

    Article  PubMed  CAS  Google Scholar 

  39. Hansson L, Lindholm LH, Niskanen L, et al., for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6

    Article  PubMed  CAS  Google Scholar 

  40. Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 407–13

    Article  PubMed  CAS  Google Scholar 

  41. Johannesson M. The cost-effectiveness of the switch to more expensive antihypertensive drugs. Health Policy 1994; 28: 1–13

    Article  PubMed  CAS  Google Scholar 

  42. Ramsay L, Williams B, Johnston G, et al. Guidelines for the management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569–92

    Article  PubMed  CAS  Google Scholar 

  43. Dahlof B. Angiotensin-converting enzyme inhibitors and effects on left ventricular hypertrophy. Blood Press Suppl 1994; 2: 35–40

    PubMed  CAS  Google Scholar 

  44. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group. N Engl J Med 1993; 329: 1456–62

    Article  PubMed  CAS  Google Scholar 

  45. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–38

    PubMed  CAS  Google Scholar 

  46. Himmelmann A, Hansson L, Hansson BG, et al. Long-term renal preservation in essential hypertension: angiotensin converting enzyme inhibition is superior to beta-blockade. Am J Hypertens 1996; 9: 850–3

    Article  PubMed  CAS  Google Scholar 

  47. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997; 127: 337–45

    PubMed  CAS  Google Scholar 

  48. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999; 354: 359–64

    Article  PubMed  CAS  Google Scholar 

  49. Kaplan NM. Combination therapy for systemic hypertension. Am J Cardiol 1995; 76: 595–7

    Article  PubMed  CAS  Google Scholar 

  50. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 1996; 17 Suppl. A: 8–15

    Article  PubMed  Google Scholar 

  51. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalizations: a literature analysis and cost of hospitalization estimate. J Res Pharmaceut Econ 1990; 2: 19–33

    Google Scholar 

  52. Urquhart, J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999; 15 (3): 217–28

    Article  PubMed  CAS  Google Scholar 

  53. Skaer TL, Sclar DA, Robison LM. Noncompliance with antihypertensive therapy. Pharmacoeconomics 1996; 9 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  54. Jones JK, Gorkin L, Lian JF, et al. Discontinuation and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293–5

    Article  PubMed  CAS  Google Scholar 

  55. McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–26

    Article  PubMed  CAS  Google Scholar 

  56. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 533–7

    Article  PubMed  CAS  Google Scholar 

  57. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 1997; 10: 697–704

    Article  PubMed  CAS  Google Scholar 

  58. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19: 1446–57

    Article  PubMed  CAS  Google Scholar 

  59. Caro JJ, Speckman JL. Existing treatment strategies: does noncompliance make a difference? J Hypertens 1998; 16 Suppl. 7; S31-S34

    Google Scholar 

  60. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160: 41–6

    PubMed  CAS  Google Scholar 

  61. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64

    Article  PubMed  CAS  Google Scholar 

  62. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a meta-analysis of clinical trials. Am J Hypertens 1992; 5: 125–33

    PubMed  CAS  Google Scholar 

  63. Waeber B, Brunner HR. Combination antihypertensive therapy: does it have a role in rational therapy? Am J Hypertens 1997; 101: 31S-137S

    Google Scholar 

  64. Weber MA. Strategies for improving blood pressure control. Am J Hypertens 1998; 11: 897–9

    Article  PubMed  CAS  Google Scholar 

  65. Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens 1999; 21: 875–84

    Article  PubMed  CAS  Google Scholar 

  66. Kaplan NM. Low dose combinations in the treatment of hypertension: theory and practice. J Hum Hypertens 1999; 13: 707–10

    Article  PubMed  CAS  Google Scholar 

  67. Sever P. The heterogeneity of hypertension: why doesn’t every patient respond to every antihypertensive drug? J Cardiovasc Pharmacol 1998; 31 Suppl. 2: S1-S4

    Article  Google Scholar 

  68. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. Circulation 2000; 101: 329–35

    Article  PubMed  CAS  Google Scholar 

  69. 1999 World Health Organization — International Society of Hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999; 17 (2): 151–83

    Google Scholar 

  70. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62

    Article  PubMed  CAS  Google Scholar 

  71. Waeber B, Brunner HR. Main objectives and new aspects of combination treatment of hypertension. J Hypertens Suppl 1995; 13: S15-S19

    Article  Google Scholar 

  72. Chalmers J, Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000; 18: 1–11

    Article  Google Scholar 

  73. Fagan TC. Remembering the lessons of basic pharmacology. Arch Intern Med 1994; 154: 1430–1

    Article  PubMed  CAS  Google Scholar 

  74. Dusing R, Weisser B, Mengden T, et al. Changes in antihypertensive therapy - the role of adverse effects and compliance. Blood Press 1998; 7: 313–5

    Article  PubMed  CAS  Google Scholar 

  75. Chanudet X, Phong Chau N, de Champvallins M. Very-low-dose perindopril 2 mg/indapamide 0.625 mg combination gives higher response and normalization rates than losartan 50 mg in the treatment of essential hypertension [abstract no. P2.43]. J Hypertens 2000; 18 Suppl. 2: S100

    Google Scholar 

  76. Levy BI, Delafosse JM, Duriez M, et al. Effect of low doses of perindopril and indapamide alone or in combination (Preterax) in renovascular hypertensive rats. Eur Heart J 1999; 1 Suppl. L: L50-L57

    Google Scholar 

  77. Rakusan K, Cicutti N, Maurin A, et al. The effect of treatment with low dose ACE inhibitor and/or diuretic on coronary microvasculature in stroke-prone spontaneously hypertensive rats. Microvasc Res 2000; 59: 243–54

    Article  PubMed  CAS  Google Scholar 

  78. Hilleman DE, Wadibia EC, Lucas BD. Cost savings associated with therapeutic interchange in the treatment of mild-to-moderate hypertension. Pharm Ther 1998; 23: 558, 563–9

    Google Scholar 

  79. Cost effectiveness of combination therapy. Based on a presentation by Daniel Hilleman, PharmD. Am J Manag Care 1999; 5 (7 Suppl.): S449-S455

    Google Scholar 

  80. Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol and enalapril in the treatment of hypertension. Clin Exper Hypertens 1998; 20: 833–46

    Article  CAS  Google Scholar 

  81. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4

    Article  PubMed  CAS  Google Scholar 

  82. Luscher TF, Vetter H, Siegenthaler W, et al. Compliance in hypertension: facts and concepts. J Hypertens Suppl 1985; 3: S3-S9

    Google Scholar 

  83. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 3423: 145–53

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Medica III, Policlinico S. Orsola, University of Bologna, Via Massarenti 9, I-40138, Bologna, Italy

    Ettore Ambrosioni

Authors
  1. Ettore Ambrosioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ettore Ambrosioni.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ambrosioni, E. Pharmacoeconomics of Hypertension Management. Pharmacoeconomics 19, 337–347 (2001). https://doi.org/10.2165/00019053-200119040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200119040-00002

Keywords

Search

Navigation